Risk of potential drug-drug interactions in the cardiac intensive care units

References

1. ↵
   1. Cooke FL,
   2. Bartram T

   (2015) Guest editors'introduction:human resource management in health care and elderly care:current challenges and toward a research agenda. Human Resource Management 54:711–735.

   OpenUrl
2. ↵
   1. Shakeel F,
   2. Khan JA,
   3. Aamir M,
   4. Asim SM,
   5. Ullah I

   (2018) A multicentered pharmacoepidemiological approach to evaluate clinically significant potential drug–drug interactions in medical intensive care settings in Pakistan. Hong Kong Journal of Emergency Medicine 25:190–195.

   OpenUrl
3. ↵
   1. Tesfaye ZT,
   2. Nedi T

   (2017) Potential drug–drug interactions in inpatients treated at the Internal Medicine ward of Tikur Anbessa Specialized Hospital. Drug Healthc Patient Saf 9:71–76.

   OpenUrl
4. ↵
   1. Bethi Y,
   2. Shewade DG,
   3. Dutta TK,
   4. Gitanjali B

   (2017) Prevalence and predictors of potential drug–drug interactions in patients of internal medicine wards of a tertiary care hospital in India. European Journal of Hospital Pharmacy 0:1–6.
5. ↵
   1. Goh I,
   2. Lai O,
   3. Chew L

   (2018) Prevalence and risk of polypharmacy among elderly cancer patients receiving chemotherapy in ambulatory oncology setting. Curr Oncol Rep 20:38.

   OpenUrl
6. ↵
   1. Misra A,
   2. Tandon N,
   3. Ebrahim S,
   4. Sattar N,
   5. Alam D,
   6. Shrivastava U,
   7. et al.

   (2017) Diabetes, cardiovascular disease, and chronic kidney disease in South Asia:current status and future directions. BMJ 357:j1420.

   OpenUrlFREE Full Text
7. ↵
   1. Roth GA,
   2. Johnson C,
   3. Abajobir A,
   4. Abd-Allah F,
   5. Abera SF,
   6. Abyu G,
   7. et al.

   (2017) Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 70:1–25.

   OpenUrlFREE Full Text
8. ↵
   1. Sharma S,
   2. Chhetri HP,
   3. Alam K

   (2014) A study of potential drug-drug interactions among hospitalized cardiac patients in a teaching hospital in Western Nepal. Indian J Pharmacol 46:152–156.

   OpenUrl
9. ↵
   1. Armahizer MJ,
   2. Seybert AL,
   3. Smithburger PL,
   4. Kane-Gill SL

   (2013) Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care 28:243–249.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Cruciol-Souza JM,
    2. Thomson JC

    (2006) Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci 9:427–433.

    OpenUrlPubMed
11. ↵
    1. Smithburger PL,
    2. Kane-Gill SL,
    3. Seybert AL

    (2010) Drug-drug interactions in cardiac and cardiothoracic intensive care units. Drug Safety 33:879–888.

    OpenUrlCrossRefPubMed
12. ↵
    1. Zwart-van Rijkom JE,
    2. Uijtendaal EV,
    3. Ten Berg MJ,
    4. Van Solinge WW,
    5. Egberts AC

    (2009) Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol 68:187–193.

    OpenUrlCrossRefPubMed
13. ↵
    1. Bhuiyan P,
    2. Rege N

    (2001) ICH Harmonised Tripartite Guideline:guideline for good clinical practice. Journal of Postgraduate Medicine 47:ISSN: 0972-2823.
14. 1. Murtaza G,
    2. Khan MYG,
    3. Azhar S,
    4. Khan SA,
    5. Khan TM

    (2016) Assessment of potential drug–drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J 24:220–225.

    OpenUrl
15. 1. Ismail M,
    2. Iqbal Z,
    3. Khattak MB,
    4. Khan MI,
    5. Javaid A,
    6. Khan TM

    (2012) Potential drug-drug interactions in cardiology ward of a teaching hospital. Health Med 6:1618–1624.

    OpenUrl
16. ↵
    1. Ramalingam K,
    2. Rajagopal SS,
    3. Kandasamy K,
    4. Krishnan K

    (2018) A prospective study on potential drug interactions among hospitalized patients in the cardiology departments in tertiary care hospitals. Indian Journal of Applied Research 8:65–68.

    OpenUrl
17. ↵
    1. Carvalho REFLd,
    2. Reis AMM,
    3. Faria LMPd,
    4. Zago KSdA,
    5. Cassiani SHDB

    (2013) Prevalence of drug interactions in intensive care units in Brazil. Acta Paulista de Enfermagem 26:150–157.

    OpenUrl
18. ↵
    1. Fairweather D,
    2. Cooper LT,
    3. Blauwet LA

    (2013) Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 38:7–46.

    OpenUrlCrossRefPubMed
19. ↵
    1. Koch MB,
    2. Davidsen M,
    3. Andersen LV,
    4. Juel K,
    5. Jensen GB

    (2015) Increasing prevalence despite decreasing incidence of ischaemic heart disease and myocardial infarction. A national register based perspective in Denmark, 1980-2009. Eur J Prev Cardiol 22:189–195.

    OpenUrlCrossRefPubMed
20. ↵
    1. Rafieii H,
    2. Arab M,
    3. Ranjbar H,
    4. Arab N,
    5. Sepehri G,
    6. Amiri M

    (2012) The prevalence of potential drug interactions in Intensive Care Units. Journal of Critical Care Nursing 4:191–196.

    OpenUrl
21. ↵
    1. Guthrie B,
    2. Makubate B,
    3. Hernandez-Santiago V,
    4. Dreischulte T

    (2015) The rising tide of polypharmacy and drug-drug interactions:population database analysis 1995-2010. BMC Med 13:74.

    OpenUrlCrossRefPubMed